Lisata (LSTA) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, Nov. 6, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Dr. David…
63,480$
Echtzeit-Aktienkurs CATALENT
Bid:
Ask:
Nachrichten zur CATALENT Aktie
Lisata Therapeutics CEO discusses Catalent deal
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces…
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Lisata Therapeutics announces research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Galapagos inks agreement with Catalent for experimental CAR-T therapy
…
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker…
Novo Holdings completes $16.5 billion takeover of Catalent By Reuters
Novo Holdings completes $16.5 billion takeover of Catalent…
Novo Holdings completes $16.5 bln takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after…
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s…
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global…
Novo Holdings $16.5 billion Catalent buy wins EU antitrust approval By Reuters
Novo Holdings $16.5 billion Catalent buy wins EU antitrust approval…
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal By Reuters
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal…
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings By Reuters
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings…
Catalent reports Q1 loss, misses market expectations By Investing.com
Catalent reports Q1 loss, misses market expectations…
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the…
Roche comes out against clearing takeover of drug manufacturer Catalent By Reuters
Roche comes out against clearing takeover of drug manufacturer Catalent…
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout By Reuters
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout…
Catalent to sell New Jersey facility By Reuters
Catalent to sell New Jersey facility…
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Ardena acquires Catalents Somerset, NJ facility, expanding its US presence and boosting advanced oral drug product manufacturing capabilities.…
Catalent delays filing of annual report By Reuters
Catalent delays filing of annual report…
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent By Reuters
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent…
CDMO executive says Novo purchase of Catalent may help competition - CTFN
…
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalents (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical…
Global Dermal Toxicity Testing Market Size To Exceed USD 4.95 Billion By 2033 | CAGR of 8.11%
The Global Dermal Toxicity Testing Market Size was Valued at USD 2.27 Billion in 2023 and the Worldwide Dermal Toxicity…
Catalent exec sells over $76k in company stock By Investing.com
Catalent exec sells over $76k in company stock…
Catalents (CTLT) Latest Partnership to Boost Clinical Trials
Catalents (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving…
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.…
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
Robbins LLP is investigating the acquisition of Catalent, Inc. (CTLT) by Novo Holdings to determine if it is in the…
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal
Ares Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of…
Catalent executive sells $21,749 in company stock By Investing.com
Catalent executive sells $21,749 in company stock…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…